66 results about "Myocardial disease" patented technology

The present invention relates to methods of using granulocyte colony stimulating factor (G-CSF) polypeptide, alone and in conjunction with stromal cell derived factor (SDF-1) polypeptide, to increase the mobilization of c-Kit+ stem cells in the blood, bone marrow, tissue, heart or other organs for the subsequent production of embryoid body-like cell clusters. These embryoid body-like cell clusters can be used for cell replacement therapy, for the treatment of cardiac myopathy and other diseases and disorders, and for screening agents that drive or inhibit differentiation and proliferation.

Compositions and methods for imaging and for chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns agents comprising a targeting moeity comprising a beta-adrenergic receptor targeting compound conjugated or embedded with ethylenediamine. The present invention also concerns methods of application of such agents for imaging and treatment of cardiovascular diseases, and kits for preparing a radiolabeled therapeutic or diagnostic agent.

The invention relates to the technical field of biology and particularly relates to a non-treatment-purpose method for screening mutation of pathogenic genes relevant with hypertrophic cardiac myopathy. The method comprises the following steps: (1) extracting genomes; (2) carrying out multiplex PCR amplification on target genes; (3) constructing a target gene library; and (4) sequencing the target gene library by virtue of a next-generation semiconductor sequencing platform, and screening gene mutation sites relevant with the hypertrophic cardiac myopathy. The method is simple, convenient, rapid and low in cost, multiple samples can be detected once, the foundation is laid for the screening of the hypertrophic cardiac myopathy, and the road is exploited for the clinic molecular diagnosis.

The invention relates to a medical examination and diagnosis method and instrument, in particular to a multi-dimensional electrocardio ultrasonic signal fusion computed tomography imaging system and method based on anatomical orientation. A multi-dimensional ultrasonic cardiac structure and a perfusion image technology are further integrated on the basis of a multi-dimensional electrocardiosignal imaging system and method, and a novel non-invasive platform is provided for recording and evaluating the electro-mechanical signal characteristic and myocardial perfusion characteristic of heart. The method is a unique electrocardio-mechanical function and perfusion synchronized computed tomography imaging method based on anatomical orientation, and the technology is a non-invasive imaging technology for detecting transmural cardiac electrical activity information and mechanical signals. By adopting the medical examination and diagnosis method and instrument, the diagnosis of myocardial diseases such as cardiac hypertrophy, cardiomyopathy, myocardial infarction and myocarditis, the determination of the origin of arrhythmia, and the like can be enhanced, and a brand-new diagnosis and guide treatment tool is provided for rapid real-time diagnosis of heart diseases.

The invention relates to medical examination and diagnosis methods and instruments, in particular to a multi-dimensional electrocardiosignal imaging system and method. The body surface electric potential mapping technology and the electrocardio vector technology are integrated, a new non-invasive platform is provided for recording the heart-across-myocardium electrical activity information, and in other words, a new non-invasive body surface heart-across-myocardium electrical activity information imaging method and technology which are formed by combining the vector center 0 point galvanic coupling and body surface electric potential mapping technology and are similar to satellite positioning are provided. The non-invasive electrocardio function imaging method and technology for detecting heart-across-myocardium electrocardio activity information with the dissection positioning as a basis are provided. According to the multi-dimensional electrocardiosignal imaging system and method, the arrhythmia reason can be determined, the cardiac muscle diseases such as myocardial hypertrophy, cardiomyopathy, myocardial infarction and myocarditis can be diagnosed, and a brand new diagnosis tool is provided for fast diagnosing the heat diseases in real time.

The present invention relates to a Chinese medicine for curing high blood pressure and myocardial diseases, which is prepared with 10 portions of ginseng, 20 portions of astragalus root, 10 portions of cassia twig, 10 portions of cassia barkcassia bark, 5 portions of red sage root, 15 portions of safflower, 10 portions of radix polygoni multiflori preparata, 10 portions of Chinese wolfberry, 10 portions of malaytea scurfpea fruit , 10 portions of oriental waterplantain rhizome, 10 portions of fourstamen stephania root, 10 portions of eucommia bark, 10 portions of Chinese magnoliavine fruit, 10 portions of doubleteeth pubescent angelica root, 15 portions of suberect spatholobus stem, 15 portions of Chinese taxillus twig, 10 portions of szechuan lovage rhizome, 10 portions of turmeric root-tuber, 10 portions of notoginseng, 10 portions of costus root, 10 portions of figwort root and 5 portions of liquoric root. The Chinese medicine mainly treats myocardial diseases such as coronary heart disease, angina pectoris and high blood pressure.

The invention provides a traditional Chinese medicine preparation for treating pediatric viral myocarditis. The preparation comprises raw materials of Radix Ophiopogon, therootofred-rootedsalvia, cassia twig, alliummacrostemon, rootofcommonpeony, Schisandra chinensis, pseudo-ginseng, Astragalusmongholicus, Fructus Trichosanthis, Fructus Forsythiae, Semen Platycladi, Rhizoma Atractylodis, luffa vegetable sponge, angelica, Ligusticumwallichii, curcuma zedoary, ginger processed pinellia, the root of large-flowered skullcap, polygala root, earthworm, and Radix aucklandiae. The invention aims to prepare a medicine for treating myocarditis from selected traditional Chinese medicines. The prepared medicine not only can improve the metabolism of myocardium and myocardial nutrition, protect the heart cells and improve myocardial disease resistance, but also can directly kill virus, reduce the damage of virus on myocardium, and realize combination of antivirus and overall regulation; and the medicine can reduce deputy effects caused by long-term application of Western medicine on the human body, and is an ideal medicine for treating myocarditis. In addition, the medicine prepared by the invention contains a large amount of active ingredients, employs cheap raw materials and simple preparation method, and can be widely used in clinical practice.

A surface attached cardiac function monitor and / or intervention system comprises of a cardiac support device, a cardiac function monitor device and / or intervention device. Cardiac support device is attached on an external or internal surface of a cardiac chamber and supports it. The cardiac function monitor device is connected with a biochemical and physiological sensor. The physiological and biochemical sensor transmits variations of biochemical and physiological parameters that are received by the cardiac function monitor device. The intervention device has at least one member selected from pressure intervention device, an electrical / magnetic stimulation intervention device and a medicine intervention device. This medical system of the present invention could help in diagnosis as well as treatment of the heart failure and other myocardial diseases to improve the condition of patient. It could also be helpful for the monitoring, diagnosis and treatment of diseases of lungs, kidney, liver, spleen, stomach and bladder, etc.

The present invention relates to 3,4-dihydroquinazoline derivatives as T-type calcium channel blockers and a method of preparing the same. The present invention further relates to a composition comprising the same. The composition comprising the 3,4-dihydroquinazoline derivatives of the present invention can be effectively used for preventing and treating angina pectoris, high blood pressure, myocardial disease, pain and epilepsy by blocking the T-type calcium channel.

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of familial amyloid polyneuropathy may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of transthyretin-related hereditary amyloidosis, neurodegenerative diseases, amyloidosis, neuropathic pain, amyloid fibril formation and cardiomyopathy related diseases.

Preparation of azetidinone compounds and medical use thereof are provided by the present invention. More particularly, azetidionne compounds, shown as formula (I), wherein R1, R2, R3, R4, R5 and R6 are defined in description, and preparation methods thereof are provided by the present invention. The compounds of the present invention can reduce the levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) in plasma, and can be used as medicaments for reducing cholesterol in blood. Therefore the compounds of the present invention can be used to treat or prevent diseases of atherosclerosis, cacergasia of blood vessel, cardiac failure, coronary artery disease, angiocardiopathy, myocardial, angina, hyperlipoidemia and hypercholesteremia and the like. Preparation method of compounds of formula (I) and intermediate compounds are also provided by the present invention.

The invention relates to a labeling technique of 99Tcm-His10-Annexin V and the applications of the 99Tcm-His10-Annexin V as an imaging agent in terms of apoptosis under the condition of detecting diseases. By applying a direct labeling method, the invention utilizes SnCl2 . 2H2O reductant and citrate buffer to carry out 99Tcm labeling on His10-Annexin V. The method has the advantages of simple and convenient operation and low cost. Experiments on animals show that the injected 99Tcm-His10-Annexin V can clearly display the apoptosis of different tissues, such as cardiac muscle, tumor, etc., and can be applied to the diagnosis of myocardial lesions, the efficacy evaluation of tumor chemotherapy, etc.

A compound of formula (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, Wherein Q, R2, Ar, A and R1 are as defined in claim 1. The claimed compounds are gap junction blockers useful for the treatment or prevention of a range of conditions including migraine, epilepsy, non-epileptic seizures, brain injury (including stroke, intracranial haemorrhage and trauma induced), pain, neurodegenerative disease or cardiovascular disease including myocardial infarction, coronary revascularization or angina.

Preparation of azetidinone compounds and medical use thereof are provided by the present invention. More particularly, azetidionne compounds, shown as formula (I), wherein R1, R2, R3, R4, R5 and R6 are defined in description, and preparation methods thereof are provided by the present invention. The compounds of the present invention can reduce the levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) in plasma, and can be used as medicaments for reducing cholesterol in blood. Therefore the compounds of the present invention can be used to treat or prevent diseases of atherosclerosis, cacergasia of blood vessel, cardiac failure, coronary artery disease, angiocardiopathy, myocardial, angina, hyperlipoidemia and hypercholesteremia and the like. Preparation method of compounds of formula (I) and intermediate compounds are also provided by the present invention.

The invention relates to application of an oral hypoglycemic peptide. The application is used for preparing a medicine or a medicine composition for treating or preventing diabetes complicated with cardiovascular diseases. The oral hypoglycemic peptide is polypeptide OHP2. The polypeptide can effectively improve myocardial hypertrophy and fibrosis damage caused by the diabetes, reduce the contentof related myocardial enzymes, adjust the lipid metabolism level and improve myocardial cell oxidative stress and mitochondrial damage, so that the effect of protecting the heart is achieved; and therefore, the polypeptide can be used as a candidate molecule for treating or preventing the diabetes complicated with the cardiovascular diseases (especially diabetic cardiomyopathy), and has a good application prospect.

The invention relates to a medical examination diagnostic method and instrument, in particular to an electrocardio tomography imaging system and method. The electrocardio tomography imaging method is unique, is based on anatomical positioning, and is a non-invasive imaging technology used for detecting transmural electrocardio activity information (including a heart transmural electric potential, an electrocardiogram, an electrocardio activation map depolarization mode, and an electrocardio activation map repolarization mode). According to the electrocardio tomography imaging system and method, diagnosis of myocardium diseases such as myocardial hypertrophy, cardiomyopathy, myocardial infarction and myocarditis can be improved, sources of arrhythmia can be determined, and a novel diagnosis and treatment guidance tool is provided for quick real-time diagnosis of myocardial diseases.

The invention describes and claims the use of vasopeptidase inhibitors of formula (I) for the treatment of nephropathy in diabetic or non-diabetic patients, including diabetic or non-diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndome, hypertensive nephrosclerosis, microalbuminuria or end stage renal disease, or insulin resistance or of metabolic diseases associated with advanced glycation end-products, such as diabetic complications, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, myocardial infarction and / or diabetic cardiomyopathy, or atherosclerosis or endothelial dysfunction.

The invention relates to a composition for treating myocardial diseases, femoral head necrosis and a tumor, which comprises the following raw material medicaments in parts by weight: 10 to 150 parts of panax pseudoginseng, 20 to 200 parts of gen-seng, 10 to 100 parts of frankincense, 10 to 100 parts of myrrh, 10 to 150 parts of eupolyphaga, 10 to 150 parts of keel, 5 to 100 parts of natural copper, 1 to 10 parts of artificial musk, 10 to 150 parts of aconitum szechenyianum, 10 to 120 parts of bryozoatum and 5 to 150 parts of indigo. The invention also discloses a preparation process of the composition. The composition has the functions of supplementing qi, promoting blood circulation for removing blood stasis, strengthening body resistance and eliminating evil, and removing blood stasis for promoting tissue regeneration, and can simultaneously treat the myocardial diseases, avascular necrosis diseases of the femoral head and inhibit the tumor.

The present invention relates to a human functional gene, especially CR-1 gene related to cell reconstitution, conduction and death. The gene is obtained through the comprehensive technological process of cDNA selection, EST location, genome DNA sequence analysis, PCR reaction and cloning end expanding, etc. Experiments including Northern and Western cross breeding detection of CR-1 gene expression in tumor cell, RNA interference immunohitochemistry detection of the expressino of CR-1 in myocardial tissue of myocardial disease patient, systemic research of the expression of CR-1 interacted protein and CR-1 gene in coliform bacteria and euaryotice cell, etc. show that the gene may be used as the target site in clinical diagnosis and treatment of myocardial disease and tumors.

The invention provides an astaxanthin and doxorubicin combined preparation and an application thereof. The astaxanthin and doxorubicin combined preparation comprises astaxanthin and doxorubicin, wherein the molar concentration ratio of astaxanthin to doxorubicin is (0.5-2.5) to 1; and preparation is an injection preparation or an oral preparation. The astaxanthin and doxorubicin combined preparation is applied to doxorubicin cardiomyopathy. Influence of the astaxanthin and doxorubicin combined preparation on doxorubicin side effects are analyzed from the aspects of myocardial cell activity, mitochondrial membrane potential, inflammatory factor NF-kB signal path; and in addition, relevant experiments of astaxanthin on the doxorubicin anti-tumor activity are carried out, and prove that the astaxanthin can lower doxorubicin cardiotoxicity by protecting mitochondria and regulating the inflammatory factor NF-kB signal path, and has the effect of improving the doxorubicin anti-tumor activity, wherein the best effect can be achieved by joint treatment of 2[mu]m of astaxanthin and 1[mu]m of doxorubicin.

The invention provides a traditional Chinese medicine preparation for treating pediatric viral myocarditis. The preparation comprises raw materials of Radix Ophiopogon, therootofred-rootedsalvia, cassia twig, alliummacrostemon, rootofcommonpeony, Schisandra chinensis, pseudo-ginseng, Astragalusmongholicus, Fructus Trichosanthis, Fructus Forsythiae, Semen Platycladi, Rhizoma Atractylodis, luffa vegetable sponge, angelica, Ligusticumwallichii, curcuma zedoary, ginger processed pinellia, the root of large-flowered skullcap, polygala root, earthworm, and Radix aucklandiae. The invention aims to prepare a medicine for treating myocarditis from selected traditional Chinese medicines. The prepared medicine not only can improve the metabolism of myocardium and myocardial nutrition, protect the heart cells and improve myocardial disease resistance, but also can directly kill virus, reduce the damage of virus on myocardium, and realize combination of antivirus and overall regulation; and the medicine can reduce deputy effects caused by long-term application of Western medicine on the human body, and is an ideal medicine for treating myocarditis. In addition, the medicine prepared by the invention contains a large amount of active ingredients, employs cheap raw materials and simple preparation method, and can be widely used in clinical practice.

The present invention aims to provide an artificial tissue that can efficiently reproduce myocardial tissue function and that can be used in an actual implantation and produced by culturing. The present invention relates to a graft material for treating myocardial disease, the graft material including a cell sheet containing adipocytes.

The invention provides a traditional Chinese medicine for treating dilated cardiomyopathy and a preparation method thereof. The traditional Chinese medicine comprises stellaria media, liverwort, adiantum capillus-veneris, tiarella polyphylla, psammosilene tunicoides, centaury, woolly speedwell, phlomis umbrosa, rattan, euphorbia maculata, stauntonia latifolia, vervain, emblic leafflower fruits, herba aconiti, small-leaved desmodium roots, asteris souliei, anemone rivularis and indian pentanema herb. For treating dilated cardiomyopathy, the traditional Chinese medicine disclosed by the invention has the advantages of being low in side effect, good in curative effect, low in cost, high in cure rate, free from drug resistance, convenient to take and the like; and the traditional Chinese medicine disclosed by the invention has great advantages for improving symptoms and physical signs of patients suffering from dilated cardiomyopathy, adjusting the heart function class and increasing the survival rate of patients.

The invention relates to the technical field of medicines, in particular to application of quercetin and kaempferol in preparation of products for preventing or treating hereditary cardiomyopathy. The hereditary cardiomyopathy comprises dilated cardiomyopathy, hypertrophic cardiomyopathy and restricted cardiomyopathy. According to the product for preventing or treating cardiomyopathy, accumulation of active oxygen in myocardial cells and superoxide in mitochondria is reduced, intracellular DNA damage caused by ROS accumulation is relieved, the contractility of the myocardial cells is increased, and cardiomyopathy is prevented or treated. The new application of the quercetin and the kaempferol provides a new choice for development of drugs for preventing or treating the hereditary cardiomyopathy, expands the application range of the quercetin and the kaempferol, provides a new direction for clinical treatment of the hereditary dilated cardiomyopathy, and also brings a new vitality for clinical application of Chinese herbal medicine substances.

The invention provides a gene engineering method for improving age-related senescence of mesenchymal stem cells of aged rats. The method comprises the following steps: putting passage-stable mesenchymal stem cells obtained from marrow of the aged rats in a conventional culture medium provided with TPP1 overexpression slow virus particles (MOI is 100), infecting for 24 hours, and then replacing the culture medium into the conventional culture medium, adding puromycin in concentration of 5 microgrammes per microliter after 3 days, screening for 7 days, and applying the screened mesenchymal stem cells to cell transplantation therapy. The method has the beneficial effects that through overexpression of TPP1 in the mesenchymal stem cells of the aged rats, the age-related senescence of the mesenchymal stem cells of the aged rats can be obviously improved, so that the purpose of improving the effect of treating ischemic myocardial diseases can be achieved.

Compositions and methods for imaging and for chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns agents comprising a targeting moeity comprising a beta-adrenergic receptor targeting compound conjugated or embedded with ethylenediamine. The present invention also concerns methods of application of such agents for imaging and treatment of cardiovascular diseases, and kits for preparing a radiolabeled therapeutic or diagnostic agent.

The invention relates to a medical examination and diagnosis method and instrument, in particular to a multi-dimensional electrocardiographic signal imaging system and method. The present invention integrates body surface potential mapping technology and ECG vector technology, and provides a new non-invasive platform to record the information of cardiac transmural electrical activity, that is, based on the combination of vector center 0-point galvanic couple and body surface potential mapping technology A new imaging method and technology similar to satellite positioning non-invasive cardiac transmural electrical activity information has been formed. It is a non-invasive electrocardiographic functional imaging method and technology for detecting transmural electrocardiographic activity information based on anatomical positioning. The invention can help determine the origin of arrhythmia, and diagnose myocardial diseases such as myocardial hypertrophy, cardiomyopathy, myocardial infarction, myocarditis, etc., and provides a brand-new diagnostic tool for rapid and real-time diagnosis of heart diseases.